免疫检查点抑制剂治疗患者免疫相关不良事件管理:美国临床肿瘤学会临床实践指南
该指南由多学科、多组织专家小组制定,系统综述聚焦2000年至2017年发表的指南、系统评价与Meta分析、随机对照试验和病例系列,共纳入204篇合格文献。由于高质量证据缺乏,推荐基于专家共识。指南按器官系统给出毒性诊断与管理推荐,并给出按毒性分级的一般管理原则。对急诊科与ICU医生而言,需掌握ICPi相关毒性的分级处理框架,尤其是3级及以上毒性的激素启动与ICPi暂停或永久停用原则。
要点
- 3级毒性一般需暂停ICPi并启动大剂量糖皮质激素:泼尼松1至2 mg/kg/d或甲泼尼龙1至2 mg/kg/d。
- 糖皮质激素应在至少4至6周内逐渐减量。
- 4级毒性一般推荐永久停用ICPi,但已用激素替代控制的内分泌病除外。
- 1级毒性一般继续ICPi并密切监测,但某些神经、血液和心脏毒性例外。
- 多数2级毒性可暂停ICPi,症状恢复至1级或以下时可考虑恢复用药,可给予糖皮质激素。
适用人群与场景
- 接受免疫检查点抑制剂(ICPi)治疗并出现免疫相关不良事件的患者。
诊断标准与关键阈值
- 毒性按级别管理:1级、2级、3级、4级。
- 1级毒性一般继续ICPi并密切监测,但某些神经、血液和心脏毒性例外。
- 多数2级毒性可暂停ICPi,症状恢复至1级或以下时可考虑恢复用药。
- 3级毒性一般需暂停ICPi并启动大剂量糖皮质激素。
- 4级毒性一般推荐永久停用ICPi,但已用激素替代控制的内分泌病除外。
处置流程与药物剂量
- 1级毒性:一般继续ICPi并密切监测,但某些神经、血液和心脏毒性例外。
- 2级毒性:多数可暂停ICPi,可给予糖皮质激素,症状恢复至1级或以下时可考虑恢复用药。
- 3级毒性:一般暂停ICPi并启动大剂量糖皮质激素,泼尼松1至2 mg/kg/d或甲泼尼龙1至2 mg/kg/d。
- 糖皮质激素应在至少4至6周内逐渐减量。
- 难治性病例可能需要英夫利西单抗或其他免疫抑制治疗。
- 4级毒性:一般推荐永久停用ICPi,但已用激素替代控制的内分泌病除外。
红旗征与不能漏的情况
- 某些神经、血液和心脏毒性在1级时即为例外,不按一般1级毒性继续ICPi处理。
研究设计与关键结果
- 系统综述共纳入204篇合格文献,证据多来自观察性数据的系统评价、共识指南、病例系列和病例报告。
- 由于免疫相关不良事件管理的高质量证据缺乏,推荐基于专家共识。
- 指南按器官系统给出毒性诊断与管理推荐。
证据类型、等级与局限
- 证据类型:美国临床肿瘤学会(ASCO)临床实践指南,基于系统综述与非正式共识过程。
- 系统综述聚焦2000年至2017年发表的指南、系统评价与Meta分析、随机对照试验和病例系列。
- 推荐基于专家共识。
- 局限:原文未报告局限性
对床旁实践的改变
- 急诊/ICU接诊ICPi治疗患者时,应按毒性分级决定ICPi是否继续、暂停或永久停用。
- 3级毒性一般需暂停ICPi并启动大剂量糖皮质激素(泼尼松1至2 mg/kg/d或甲泼尼龙1至2 mg/kg/d),激素减量至少4至6周。
- 4级毒性一般推荐永久停用ICPi,但已用激素替代控制的内分泌病除外。
- 1级毒性一般继续ICPi并密切监测,但某些神经、血液和心脏毒性例外。
- 难治性病例可能需要英夫利西单抗或其他免疫抑制治疗。
指南或共识出处
- 美国临床肿瘤学会(American Society of Clinical Oncology)临床实践指南:Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICPi) therapy. Methods A multidisciplinary, multi-organizational panel of experts in medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, urology, neurology, hematology, emergency medicine, nursing, trialist, and advocacy was convened to develop the clinical practice guideline. Guideline development involved a systematic review of the literature and an informal consensus process. The systematic review focused on guidelines, systematic reviews and meta-analyses, randomized controlled trials, and case series published from 2000 through 2017. Results The systematic review identified 204 eligible publications. Much of the evidence consisted of systematic reviews of observational data, consensus guidelines, case series, and case reports. Due to the paucity of high-quality evidence on management of immune-related adverse events, recommendations are based on expert consensus. Recommendations Recommendations for specific organ system-based toxicity diagnosis and management are presented. While management varies according to organ system affected, in general, ICPi therapy should be continued with close monitoring for grade 1 toxicities, with the exception of some neurologic, hematologic, and cardiac toxicities. ICPi therapy may be suspended for most grade 2 toxicities, with consideration of resuming when symptoms revert to grade 1 or less. Corticosteroids may be administered. Grade 3 toxicities generally warrant suspension of ICPis and the initiation of high-dose corticosteroids (prednisone 1 to 2 mg/kg/d or methylprednisolone 1 to 2 mg/kg/d). Corticosteroids should be tapered over the course of at least 4 to 6 weeks. Some refractory cases may require infliximab or other immunosuppressive therapy. In general, permanent discontinuation of ICPis is recommended with grade 4 toxicities, with the exception of endocrinopathies that have been controlled by hormone replacement. Additional information is available at www.asco.org/supportive-care-guidelines and www.asco.org/guidelineswiki .
参考来源
- Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018. PMID: 29442540. doi:10.1200/JCO.2017.77.6385
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。